Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes

Simple item page
dc.contributor.authorSued, Omar
dc.contributor.authorAmbrosioni, Juan
dc.contributor.authorDavid, Nicolás
dc.contributor.authorManzardo, Christian
dc.contributor.authorAgüero, Fernando
dc.contributor.authorClaramonte, Xavier
dc.contributor.authorPlana, Montserrat
dc.contributor.authorTuset, Montserrat
dc.contributor.authorPumarola, Tomás
dc.contributor.authorGallart, Teresa
dc.contributor.authorGatell, Jose
dc.contributor.authorMiro, Jose M
dc.date.accessioned2024-05-22T10:19:28Z
dc.date.available2024-05-22T10:19:28Z
dc.date.issued2015-7
dc.description.abstractBackground Interventions during primary HIV infection (PHI) can modify the clinical course during the chronic phase. The long-term effect of structured treatment interruptions (STI) followed by low doses of interleukin-2 (IL-2) in treated PHI patients is unknown. Methods Twelve PHI patients with viral load (VL) <20 copies/mL, CD4 cells >500 cells/mm3, and CD4/CD8 ratio >1, on antiretroviral therapy (ART) initiated within the first 90 days of infection and continued for at least 12 months were included. They underwent four STI and were then allocated (week 0 of the study) to ART alone or ART plus low doses of IL-2. ART was stopped once VL <20 copies/mL ('final stop'). Primary endpoints were VL<3000 copies/mL and CD4 cells >500 cells/mm3 at 48 weeks; secondary endpoints were immune activation, inflammatory markers until 48 weeks and the time before resuming ART (CD4 <350 cells/mm3 or AIDS) after ‘final stop’, compared between groups. Results Ten out of 12 patients were males, median age was 35 years and the main risk was men-who-have-sex-with-men. Only one out of 12 patients (in the STI group) maintained VL<3000 copies/mL and CD4 cells >500 cells/mm3 without ART at 48 weeks. All other virological and immunological parameters were comparable between groups at week 0, 'final stop' and week 48. However, the proportion of CD8-CD38+ cells, tumor necrosis factor and srIL-2 were higher in the IL-2 group at 'final stop' and week 24. All these differences vanished during follow-up. At 5 years after the final stop 3 out of 6 patients in the IL-2 group and 6 out of 6 patients in the STI group have resumed ART (P = 0.19). Conclusions STI and IL-2 failed to achieve virological control after ART interruption. STI were not deleterious in long-term follow-up, an important issue for eradication and functional cure trials.
dc.identifier.citationSued O, Ambrosioni J, Nicolás D, Manzardo C, Agüero F, Claramonte X, et al. (2015) Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes. PLoS ONE 10(7): e0131651. https://doi.org/10.1371/journal.pone.0131651
dc.identifier.other10.1371/journal.pone.0131651
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/1024
dc.relation.ispartofseriesPLoS ONE 10(7): e0131651
dc.subjectStructured Treatment Interruptions
dc.subjectIL-2
dc.subjectOutcomes
dc.titleStructured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
75_2015_Omar Sued_Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection Inflammatory Virological and Immunological Outcomes.pdf
Size:
755.31 KB
Format:
Adobe Portable Document Format
Download

Collections

Articulos científicos